Brief Report-Reference-Cited by-同舟云学术

Brief Report

Published:2016-04-15 Issue:5 Volume:71 Page:538-543
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

van Lunzen Jan,Pozniak Anton,Gatell Jose M.,Antinori Andrea,Klauck Isabelle,Serrano Oscar,Baakili Adyb,Osiyemi Olayemi,Sevinsky Heather,Girard Pierre-Marie

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference21 articles.

1. . Decline in the AIDS and death rates in the EuroSIDA study: an observational study.;Mocroft;Lancet,2003

2. Hallay H, et al..;Le Douce;Achieving a cure for HIV infection: do we have reasons to be optimistic J Antimicrob Chemother,2012

3. . Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.;Monteiro;J Antimicrob Chemother,2014

4. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors.;Walker;AIDS,2002

5. Mitochondrial toxicity of antiviral drugs.;Lewis;Nat Med,1995

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-drug regimens for HIV treatment;The Lancet HIV;2022-12

2. Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial;2022-07-09

3. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort;Infectious Diseases and Therapy;2022-04-11

4. Two’s a Company, Three’s a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Naïve and Treatment-Experienced Patients Living with HIV-1;Infectious Diseases and Therapy;2020-03-19

5. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety;Journal of Global Antimicrobial Resistance;2020-03